525
Participants
Start Date
November 30, 2007
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2012
riferminogene pecaplasmid
"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
Placebo (for riferminogene pecaplasmid)
"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Buenos Aires
Sanofi-Aventis Administrative Office, Macquarie Park
Sanofi-Aventis Administrative Office, Vienna
Sanofi-Aventis Administrative Office, Minsk
Sanofi-Aventis Administrative Office, Diegem
Sanofi-Aventis Administrative Office, São Paulo
Sanofi-Aventis Administrative Office, Laval
Sanofi-Aventis Administrative Office, Santiago
Sanofi-Aventis Administrative Office, Prague
Sanofi-Aventis Administrative Office, Hørsholm
Sanofi-Aventis Administrative Office, Tatari
Sanofi-Aventis Administrative Office, Helsinki
Sanofi-Aventis Administrative Office, Paris
Sanofi-Aventis Administrative Office, Berlin
Sanofi-Aventis Administrative Office, Athens
Sanofi-Aventis Administrative Office, Causeway Bay
Sanofi-Aventis Administrative Office, Budapest
Sanofi-Aventis Administrative Office, Milan
Sanofi-Aventis Administrative Office, Tokyo
Sanofi-Aventis Administrative Office, México
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Singapore
Sanofi-Aventis Administrative Office, Midrand
Sanofi-Aventis Administrative Office, Seoul
Sanofi-Aventis Administrative Office, Barcelona
Sanofi-Aventis Administrative Office, Bromma
Sanofi-Aventis Administrative Office, Geneva
Sanofi-Aventis Administrative Office, Istanbul
Sanofi-Aventis Administrative Office, Kiev
Sanofi-Aventis Administrative Office, Guildford
Lead Sponsor
Sanofi
INDUSTRY